Is M&A the New R&D? - Next Generation Pharmaceuticals Summit Briefing

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

The following presentation was from the Next Generation Pharmaceuticals Summit, October 28-30, 2009 in Amelia Island, Florida. This session was the Breakfast Briefing opening the first main day of the conference and given by Frost & Sullivan. The presentation opened the session with subsequent moderation of a panel discussion around current M&A trends in the industry. http://www.ngpsummit.com/

Table of Contents

Is M&A the New R&D? - Next Generation Pharmaceuticals Summit BriefingPresentation and Panel SessionIs M&A the New R&D?




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.